Drug profile · INN
nivolumab + relatlimab
OPDUALAG
nivolumab + relatlimab (OPDUALAG) is an FDA-listed pharmaceutical active ingredient. Associated with Bristol-Myers Squibb Australia Pty Ltd.
TGA: approved
Patents linked 0
Pipeline programs 3
News articles 0
Congress events 1
Drug details — nivolumab + relatlimab
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.81
Quick answer
nivolumab + relatlimab (OPDUALAG) is an FDA-listed pharmaceutical active ingredient. Associated with Bristol-Myers Squibb Australia Pty Ltd.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Congress & event coverage
- PresentationPharma Manufacturing World
Pipeline programs
Frequently asked questions
What is nivolumab + relatlimab?
nivolumab + relatlimab (OPDUALAG) is an FDA-listed pharmaceutical active ingredient. Associated with Bristol-Myers Squibb Australia Pty Ltd.
What is the brand name for nivolumab + relatlimab?
OPDUALAG is a marketed brand name for nivolumab + relatlimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.